Taysha Gene Therapies Inc Cash Flow-to-Debt Ratio
Taysha Gene Therapies Inc cash flow-to-debt ratio. Taysha Gene Therapies Inc (TSHA) has a Cash Flow-to-Debt Ratio of -0.49x as of June 2026, meaning its operating cash flow of $-40.42 Million could theoretically repay 0% of its total liabilities ($83.17 Million) in one year. Check cash flow reinvestment rate of Taysha Gene Therapies Inc to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Taysha Gene Therapies Inc (2019–2025)
Cash flow-to-debt ratio of Taysha Gene Therapies Inc from 2019 to 2025. Historical debt coverage capacity for Taysha Gene Therapies Inc across 7 annual periods. Check TSHA cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Taysha Gene Therapies Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Taysha Gene Therapies Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Taysha Gene Therapies Inc. For the full cash flow conversion analysis, see TSHA cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.97x | $-93.09 Million | $96.38 Million | ▼ -5.6% |
| 2024 | -0.91x | $-81.22 Million | $88.84 Million | ▼ -22.5% |
| 2023 | -0.75x | $-73.02 Million | $97.79 Million | ▼ -5.9% |
| 2022 | -0.71x | $-88.39 Million | $125.33 Million | ▲ +28.5% |
| 2021 | -0.99x | $-117.04 Million | $118.57 Million | ▲ +75.7% |
| 2020 | -4.05x | $-30.73 Million | $7.58 Million | ▼ -550.5% |
| 2019 | 0.90x | $135.00K | $150.00K | — |